Cart
sales@molnova.com
HS-10296 hydrochloride
CAS No. 2134096-03-8
HS-10296 hydrochloride( —— )
Catalog No. M20331 CAS No. 2134096-03-8
HS-10296 hydrochloride is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 240 | In Stock |
|
| 5MG | 185 | In Stock |
|
| 10MG | 312 | In Stock |
|
| 25MG | 537 | In Stock |
|
| 50MG | 737 | In Stock |
|
| 100MG | 1004 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHS-10296 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionHS-10296 hydrochloride is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
-
DescriptionHS-10296 hydrochloride is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.(In Vitro):Almonertinib (HS-10296) is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC. Additionaly, Almonertinib (HS-10296) could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q.
-
In VitroAlmonertinib (HS-10296) is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC. Additionaly, Almonertinib (HS-10296) could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationNon-small cell lung Cancer
Chemical Information
-
CAS Number2134096-03-8
-
Formula Weight562.1
-
Molecular FormulaC30H36ClN7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:83.33 mg/mL (148.25 mM; Need ultrasonic)
-
SMILESCl.COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C2CC2)c2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ivana S David P . Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line[J]. Frontiers in Medicine 2017 3.
molnova catalog
related products
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
AG18
AG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.
-
PD-161570
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
